INTRODUCTION
All-ScaleFlow™ – a revolutionary approach to the scale-up and production of mRNA-based vaccine and therapeutics
Dillico’s game-changing All-ScaleFlow™ technology offers an entirely new approach to mRNA-LNP manufacturing. All-ScaleFlow™ spells the end of multi-step scale-up and batch production processes, because it enables a single piece of equipment and one set of process parameters to manufacture any volume between 1,000 and 10 million doses. This simplifies and improves the development of mRNA vaccines and therapies, while removing major manufacturing roadblocks.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
Dillico develops and markets an automated and digitized end-to-end mRNA-LNP continuous manufacturing solution tailored to its customers’ mRNA platforms.
Dillico’s global team of innovators, scientists and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology and reshape the biopharmaceutical industry landscape with next-generation therapeutics. This means improved global healthcare access, in particular for low- and medium-income countries combating regional diseases and emerging pandemics.
NEWS
Afrigen Biologics and Dillico sign CRADA to advance mRNA manufacturing solutions
Afrigen Biologics, the development lead in the mRNA technology transfer programme and Dillico Announce Cooperative R&D Agreement to test a new continuous mRNA Manufacturing Solution adapted for low- and middle-income countries. Cape Town, [...]
Flora Binder to join Dillico as Chief Development Officer
We are pleased to announce today that Flora Binder has taken up her role of Dillico’s Chief Development Officer. “Flora has a solid expertise in mRNA process transfer in the global pharmaceutical industry and it will be a significant asset to Dillico to advance our [...]
French Tech Emergence Grant for Dillico
Dillico is pleased to announce that it has been awarded a French Tech Emergence grant by BPIFrance, which we thank. This financial support is granted to startup projects that develop a disruptive innovation [...]